HTG Molecular Diagnostics, Inc.
Simbol: HTGM
NASDAQ
0.48
USDTržna cena danes
-0.0745
Razmerje P/E
-0.0008
Razmerje PEG
1.06M
Kapaciteta MRK
- 0.00%
Donos DIV
HTG Molecular Diagnostics, Inc. (HTGM) Finančni izkazi
Bilanca stanja
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 39.4 | 12.2 | 21.9 | 28.7 | |||||||||||
balance-sheet.row.short-term-investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.net-receivables | 4.77 | 1.4 | 2.1 | 1.6 | |||||||||||
balance-sheet.row.inventory | 5.21 | 0.9 | 2 | 1.5 | |||||||||||
balance-sheet.row.other-current-assets | 4.89 | 1.1 | 1.2 | 1.1 | |||||||||||
balance-sheet.row.total-current-assets | 54.94 | 15.7 | 27.2 | 32.9 | |||||||||||
balance-sheet.row.property-plant-equipment-net | 6.65 | 1.6 | 2.5 | 2.2 | |||||||||||
balance-sheet.row.goodwill | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-investments | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.tax-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-non-current-assets | 2.88 | 0.5 | 0.8 | 0.1 | |||||||||||
balance-sheet.row.total-non-current-assets | 9.52 | 2.1 | 3.3 | 2.3 | |||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-assets | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.account-payables | 4.08 | 1.2 | 1.6 | 1.3 | |||||||||||
balance-sheet.row.short-term-debt | 19.02 | 4.3 | 5.6 | 3.7 | |||||||||||
balance-sheet.row.tax-payables | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.long-term-debt-total | 4.92 | 0.5 | 6.1 | 8.9 | |||||||||||
Deferred Revenue Non Current | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||
balance-sheet.row.other-current-liab | 8.71 | 2.8 | 2.6 | 2 | |||||||||||
balance-sheet.row.total-non-current-liabilities | 20.01 | 4.1 | 10.1 | 13.5 | |||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.capital-lease-obligations | 3.41 | 1 | 1.4 | 1.1 | |||||||||||
balance-sheet.row.total-liab | 51.81 | 12.4 | 20.1 | 20.7 | |||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.common-stock | 0.03 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.retained-earnings | -910.86 | -229.9 | -208.3 | -191.2 | |||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | -0.02 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.other-total-stockholders-equity | 923.5 | 235.3 | 218.7 | 205.7 | |||||||||||
balance-sheet.row.total-stockholders-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 64.46 | 17.8 | 30.5 | 35.2 | |||||||||||
balance-sheet.row.minority-interest | 0 | 0 | 0 | 0 | |||||||||||
balance-sheet.row.total-equity | 12.64 | 5.4 | 10.4 | 14.5 | |||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 64.46 | - | - | - | |||||||||||
Total Investments | 15.23 | 0 | 12.3 | 6.3 | |||||||||||
balance-sheet.row.total-debt | 23.94 | 4.8 | 11.7 | 12.6 | |||||||||||
balance-sheet.row.net-debt | -0.24 | -7.4 | 2.1 | -9.8 |
Izkaz denarnih tokov
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 | |||||||||||
cash-flows.row.depreciation-and-amortization | 0.49 | 0.6 | 0.7 | 1.3 | |||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -1.4 | 0.7 | |||||||||||
cash-flows.row.stock-based-compensation | 0.68 | 0.8 | 1.4 | 1.8 | |||||||||||
cash-flows.row.change-in-working-capital | -0.16 | -0.1 | -1 | -0.2 | |||||||||||
cash-flows.row.account-receivables | -0.38 | 0.7 | -0.8 | 1.6 | |||||||||||
cash-flows.row.inventory | 0.27 | 0.1 | -1.4 | -0.3 | |||||||||||
cash-flows.row.account-payables | -0.2 | -0.5 | 0.5 | 0 | |||||||||||
cash-flows.row.other-working-capital | 0.16 | -0.4 | 0.7 | -1.5 | |||||||||||
cash-flows.row.other-non-cash-items | 2.31 | 1.9 | 0.9 | 0.9 | |||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -16.83 | 0 | 0 | 0 | |||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.acquisitions-net | -99828.51 | 0 | -25018 | -72.5 | |||||||||||
cash-flows.row.purchases-of-investments | -11.15 | -7.6 | -18.6 | -12.5 | |||||||||||
cash-flows.row.sales-maturities-of-investments | 14.52 | 19.9 | 12.6 | 31.6 | |||||||||||
cash-flows.row.other-investing-activites | 99828.64 | 0.1 | 25018 | 72.5 | |||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 3.48 | 12.4 | -6.7 | 18.7 | |||||||||||
cash-flows.row.debt-repayment | -7.16 | -7.8 | -0.8 | -3.6 | |||||||||||
cash-flows.row.common-stock-issued | 2.8 | 1.4 | 10.7 | 7.5 | |||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.dividends-paid | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.other-financing-activites | 6.09 | 15 | 0.5 | 5.1 | |||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 1.73 | 8.6 | 10.4 | 9 | |||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0 | 0 | |||||||||||
cash-flows.row.net-change-in-cash | -11.62 | 2.6 | -12.8 | 11.5 | |||||||||||
cash-flows.row.cash-at-end-of-period | 24.18 | 12.2 | 9.6 | 22.4 | |||||||||||
cash-flows.row.cash-at-beginning-of-period | 35.79 | 9.6 | 22.4 | 10.9 | |||||||||||
cash-flows.row.operating-cash-flow | -16.83 | -18.4 | -16.5 | -16.3 | |||||||||||
cash-flows.row.capital-expenditure | -0.02 | 0 | -0.6 | -0.5 | |||||||||||
cash-flows.row.free-cash-flow | -16.85 | -18.4 | -17.2 | -16.7 |
Vrstica izkaza poslovnega izida
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 6.21 | 6.4 | 8.9 | 8.5 | |||||||||||
income-statement-row.row.cost-of-revenue | 4.87 | 4.6 | 4.1 | 4 | |||||||||||
income-statement-row.row.gross-profit | 1.35 | 1.8 | 4.8 | 4.6 | |||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.research-development | 6.47 | - | - | - | |||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.other-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.operating-expenses | 20.94 | 22.6 | 22.6 | 24.1 | |||||||||||
income-statement-row.row.cost-and-expenses | 25.8 | 27.2 | 26.7 | 28.1 | |||||||||||
income-statement-row.row.interest-income | 0.19 | 0.1 | 0 | 0.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||
income-statement-row.row.total-other-income-expensenet | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||
income-statement-row.row.other-operating-expenses | -0.24 | 0 | -1 | 0 | |||||||||||
income-statement-row.row.total-operating-expenses | -0.55 | -0.8 | 0.7 | -1.3 | |||||||||||
income-statement-row.row.interest-expense | 0.75 | 0.9 | 1.1 | 1 | |||||||||||
income-statement-row.row.depreciation-and-amortization | 0.55 | 0.7 | -1.7 | 1.6 | |||||||||||
income-statement-row.row.ebitda-caps | -19.29 | - | - | - | |||||||||||
income-statement-row.row.operating-income | -19.59 | -20.8 | -17.8 | -19.6 | |||||||||||
income-statement-row.row.income-before-tax | -20.14 | -21.6 | -17.1 | -20.9 | |||||||||||
income-statement-row.row.income-tax-expense | 0.01 | 0 | 0 | 0 | |||||||||||
income-statement-row.row.net-income | -20.15 | -21.6 | -17.1 | -20.9 |
Pogosto zastavljeno vprašanje
Kaj je HTG Molecular Diagnostics, Inc. (HTGM) skupna sredstva?
HTG Molecular Diagnostics, Inc. (HTGM) skupna sredstva so 17777655.000.
Kakšen je letni prihodek podjetja?
Letni prihodki so 3471815.000.
Kolikšna je stopnja dobička podjetja?
Dobiček podjetja je 0.184.
Kakšen je prosti denarni tok podjetja?
Prosti denarni tok je -4.967.
Kolikšna je neto stopnja dobička podjetja?
Čista stopnja dobička je -3.020.
Kolikšni so skupni prihodki podjetja?
Celotni prihodki so -2.946.
Kaj je HTG Molecular Diagnostics, Inc. (HTGM) čisti dobiček (čisti dobiček)?
Čisti dobiček (čisti prihodek) je -21594476.000.
Kolikšen je skupni dolg podjetja?
Skupni dolg je 4833948.000.
Kolikšni so stroški poslovanja?
Stroški poslovanja so 22623682.000.
Kolikšno je število denarnih sredstev podjetja?
Denarna sredstva podjetja so 2996409.000.